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Background: To determine the profile of metabolic abnormalities in T2DM persons with metabolic syndrome and
their non-diabetic first-degree relatives who also had metabolic syndrome in Benin City.
Methodology: This was a cross sectional case controlled study in which convenience sampling technique was
used to recruit 106 persons with T2DM, 96 people who are first degree relatives of type 2 diabetic persons and 96
controls using a interviewer administered questionnaire technique. The following were assessed: anthropometric
indices, blood pressure, serum lipid profile, fasting blood sugar, proteinuria, and microalbuminuria. The data
obtained were analyzed using the statistical software-Statistical package for social sciences [SPSS] version 16. A p-value
of less than 0.05 was taken as statistically significant.
Results: The mean age (SD) of the study groups were: persons living with T2DM: 58.6 ± 11.2 years, control: 57.69 ± 60.8 years
and FDR: 57.4 ± 10.6 years. No significant age and sex differences were observed in these groups. There were more
females (59.7%) than males (40.3%) with T2DM. The prevalence of MS was 13.5%, 16.7%, and 87.1% in the control, FDR
and T2DM patients respectively. For the T2DM group of subjects, impaired fasting glycaemia was the commonest
metabolic abnormality followed by microalbuminuria, low HDL cholesterol, high LDL cholesterol,
hypercholesterolaemia and hypertriglyceridaemia in decreasing frequency. For the FDR group, low HDL cholesterol
was the commonest metabolic abnormality followed by hypertriglyceridaemia, impaired fasting glucose, high LDL
cholesterol, hypertriglyceridaemia and microalbuminuria in decreasing frequency. Hypercholesterolemia and low HDL
cholesterol were the commonest metabolic abnormalities in the control group.
Conclusion: The prevalence of the MS in persons with T2DM in Nigeria appears to be high. Secondly, there is a high
prevalence of lipid abnormalities in all the study groups.
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Clustered metabolic cardiovascular risk factors, including
type-2 diabetes mellitus, essential hypertension, obesity,
dyslipidemia and ischemic heart disease, known as the
metabolic syndrome, have been well described [1]. It is es-
timated that about a quarter of the world’s population
have the syndrome and people with this condition are
likely to have a increased cardiovascular risk compared
with people without it [2]. The risk of developing DM is
5-fold greater in people with this syndrome [3].
In 1988, Reaven [4] described a multifaceted metabolic
abnormality consisting of insulin resistance with compensa-
tory hyperinsulinaemia, T2DM, essential hypertension and
hypercholesterolaemia. This syndrome became known as
Reaven’s syndrome [5]. Today, however, the World Health
Organization (WHO) and International Diabetes Feder-
ation (IDF) use the term “Metabolic Syndrome” to de-
scribe this constellation of conditions [6,7].
It is estimated that about 20-25% of the world’s popula-
tion have the metabolic syndrome [4]. Its prevalence rates
range from 13-30% and 70-80% among the Caucasian non-
diabetic [4,5] and diabetic [6,7] populations, respectively.
Among African-Americans with T2DM, the prevalence of
the metabolic syndrome is estimated to be 70% [8].
Genetically determined insulin resistance in a setting
of suitable environmental factors is the pivotal patho-
genic mechanism underlying the metabolic syndrome
[1]. Interestingly, non-diabetic relatives of diabetics tend
to be insulin resistant [9-11]. In addition, both genetic
and/or non-genetic familial influences seem to affect the
initiation and progression of the metabolic syndrome
and also, the concordance rates for glucose intolerance,
overall obesity, and low HDL-C were significantly higher
among monozygotic than dizygotic twins, indicating a
genetic influence on these phenotypes [12]. Other fac-
tors known to be associated with MS includes Leptin [13],
beta cell dysfunction [14], and insulin resistance [15].
With the metabolic syndrome driving the twin global
epidemics of T2DM and cardiovascular disease, there is
an overwhelming moral, medical and economic impera-
tive to identify people with this syndrome early so they
can benefit from lifestyle interventions and treatment
that may alter the course of the disease. The features,
causes and consequences of the metabolic syndrome
are in a dynamic period of expanding thinking and in-
vestigation. Although there are several studies on meta-
bolic syndrome but there is no study that has reported
metabolic abnormalities among diabetics and their
non-diabetic FDR in Benin City hence the need for
this study.
Aim
To determine the profile of metabolic abnormalities in
T2DM persons with metabolic syndrome and their non-diabetic first-degree relatives who also had metabolic
syndrome in Benin City.
Methodology
This was a cross sectional case–control study carried
out in the Diabetes Clinic of the University of Benin
Teaching Hospital, (UBTH) a 500 bed Federal Govern-
ment tertiary hospital in Benin City, Edo State in the
South-south geopolitical region of Nigeria. The UBTH
receives referral cases from Edo State and neighboring
States like Delta, Ondo, Ekiti and Kogi States and the
Federal Capital Territory, Abuja. A total of 124 subjects
were recruited using convenience sampling method from
the Diabetes Clinic of the UBTH with the inclusion cri-
teria including people diagnosed as having T2DM pre-
senting to UBTH within the last 24 months using the
1999 WHO criteria [16], people aged 30 years and above,
on treatment with oral hypoglycemic drugs plus or minus
non-pharmacological therapy and not requiring insulin
for survival and finally those who consented to participate
for the study. Exclusion criteria included subjects diag-
nosed of having other types of DM, with T2DM with age
< 30 years and who declined being a part of the study. For
non-diabetic FDR of persons with type 2 diabetes mellitus,
ninety-six subjects were recruited using convenience sam-
pling method from among the out patients department of
the UBTH (General practice clinic and consultant out pa-
tients clinic) and staff of UBTH and the Inclusion criteria
included: Subject must be a first degree relative of a diag-
nosed T2DM person, should be aged 30 years and above,
should not be diagnosed of having diabetes mellitus and
finally those who consented to the study while the exclu-
sion criteria includes FDR diagnosed with diabetes melli-
tus and those that declined being a part of the study.
For control subjects, ninety-six subjects were recruited
using convenience sampling method from among the
staff of UBTH, and healthy relatives of non-diabetic pa-
tients. The inclusion criteria included non diabetic age
and sex matched adult with normal fasting blood sugar
less than 110 mg/dl while the exclusion criteria included
non-diabetics less than 30 years of age, FDR of type 2
diabetic and finally non-diabetics who declined being a
part of the study.
Ethical considerations
Ethical approval was sought from the Ethics and Research
Committee of the UBTH before the commencement of
the study.
A convenience sampling technique was used to recruit
106 persons with T2DM, 96 people who are first degree
relatives of type 2 diabetic persons and 96 controls using
a questionnaire administered technique. The following
were assessed: anthropometric indices, blood pressure,
serum lipid profile, fasting blood sugar, proteinuria, and
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lyzed using the statistical software-Statistical package for
social sciences [SPSS] version 16. Statistical comparisons
were made with student’s t-test for quantitative variables
and the Chi-square test was used for comparison of pro-
portions. A p-value of less than 0.05 was taken as sta-
tistically significant. The student t-test was used to compare
means and test for significant differences in the anthropo-
metric and the metabolic indices.
Three hundred and twenty five persons were enrolled
for this study (125 persons living with T2DM, 102 persons
who were non-diabetic first degree relatives of T2DM per-
sons and 98 non-diabetic control subjects without a his-
tory of DM in a first degree relative). Out of the 125
persons living with T2DM, 124 met the requirements for
inclusion into the stage of analysis. The person excluded
from the study had incomplete results and an irregularly
filled questionnaire. Out of the 102 non-diabetic FDR,
6 persons were dropped on account of incomplete data
while for the control group, 2 persons were dropped
for the same reason. One hundred and twenty four per-
sons with T2DM, 96 non-diabetic FDR and 96 controls
met all the requirements were included in this study. The
general total of subjects who participated fully in this
study was 316 subjects.
Anthropometric measurements of weight, height, waist
circumference and hip circumference were measured for
each subject. The weight (Wt) was measured with sub-
jects in light clothing, without shoes using a weighing
scale and recorded in kilograms [kg] measured to the
nearest 0.1 kg. The height (Ht) was measured, without
shoes and the subject standing upright and looking
straight ahead (along the coronal plane) using a stadi-
ometer and was recorded to the nearest 0.1 m. The body
mass index (BMI) was calculated by the formula: BMI =
Weight (kg)/Height2(m). The waist circumference (WC)
was taken at the point midway between the inferior mar-
gin of the rib cage and the iliac crest to the nearest
0.1 cm using the measuring tape. The hip circumference
(HC) was measured at the level of the maximal gluteal
circumference (along the greater trocanter) to the near-
est 0.1 cm with subjects standing erect, hands at the
sides and feet together. The waist: hip ratio (WHR) was
thereafter determined as the WC divided by the HC.
The blood pressure (BP) was measured to the nearest
2 mmHg using a standard mercury sphygmomanometer
with subjects in the sitting position and the arms resting
on the arms of a chair and the sphygmomanometer at
the level of the heart using the 1st and 4th Korotkoff
sounds for the systolic and diastolic BP respectively.
Laboratory investigations
All subjects were instructed to observe an overnight fast
for 8–10 hours before the day of sample collection.About 20 mls of blood was collected from the ante-
cubital vein using sterile disposable needles and syrin-
ges, for the following investigations;
1. Fasting blood sugar: − 2 mls of blood was collected
in fluoride oxalate bottles and then analyzed for
plasma glucose within one hour by the glucose
oxidase method.
2. Serum lipid profile- Blood was collected in plain
bottles, allowed to clot and the serum separated
and stored at −20°C until analyzed. The assay was
done by enzymatic method using Randox Kit.
3. Urinalysis testing for proteinuria using combi-10 test
strips and microalbuminuria using micral test kit.
There were two testing protocols: In protocol 1,
each subject was ensured to be fever free and free of
symptoms of urinary tract infection (dysuria, loin
pain and suprapubic pain) prior to urine collection
for testing as this can cause a “false proteinuria”.
Each urine sample was tested with combi-10 test
strips for protein, leukocytes, nitrites and blood. A
sample of urine with proteinuria but free of leukocytes,
nitrites and blood in the absence of fever was considered
as having overt proteinuria. Such a sample was
considered as having a “significant proteinuria”. Samples
free of protein, leukocytes, nitrites and blood were
considered for protocol 2 (test for microalbuminuria).
Subjects with history of fever, dysuria and or
suprapubic pain and those with leukocytes, nitrites
and blood in urine either alone or in whatever
combination were investigated and treated for
urinary tract infection before being allowed to be
involved in the study.
Protocol 2: Samples free of protein, leukocytes, nitrites
or blood in protocol 1 above went through this protocol
to test for microalbuminuria using micral test strips in
subjects without fever, dysuria or suprapubic tenderness.
A positive micral test is that with a colour reaction of the
test urine with standards provided by the manufacturer.
Result and discussion
Demographic characteristics
The mean age (SD) of the 124 persons living with
T2DM recruited for the study was found to be 58.6 ±
11.2 years while that of the 96 persons in the control
group was 57.69 ± 60.8 years and the mean age for FDR
group was 57.4 ± 10.6 years. No significant age and sex
differences were observed in these groups and this is
suggestive of a study with subjects well matched for
age and sex. The mean age of T2DM persons (58.6 ±
11.2 years) is higher than the value reported in Sagamu
by Alebiosu and Odusan [18] (53.4 ± 6.3 years) but very
close to the mean age of a similar study in Lagos by
Table 2 Prevalence of metabolic syndrome in the 3 study
groups using WHO criteria
Parameters
Control FDR T2DM
n (%) n (%) n (%)
N = 96 N = 96 N = 124 X2 df p
WHO CITERIA
MS 13 (13.5) 16 (16.7) 108 (87.1) 159.2 2 0.01
NO MS 83 (86.5) 80 (83.3) 16 (12.9)
MS =metabolic syndrome, FDR = first degree relatives, T2DM = type 2
diabetes mellitus.
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supports the fact that T2DM is a disease of increasing
age and that in individuals at high risk for diabetes, in-
creasing age is associated with hyperglycemia and reduced
readiness with regard to lifestyle modifications. Thus, age
should be considered when planning a lifestyle modifica-
tion program.
There were more females (59.7%) than males (40.3%)
with T2DM in this study. The high proportion of fe-
males in this study may be due to the nature of Nigerian
women in that more of them seek medical attention
than men [16]. This may be different in certain Northern
Nigerian communities where purdah is practiced. A simi-
lar trend was seen in the study by Ogbera [17] in which
out of 973 T2DM persons, 703 (72.3%) were females and
260 (26.7%) were males. The study by Alebiosu and
Odusan [18], however, had more males than females. The
exact male to female ratio of T2DM persons in Nigeria is
not known. Nyenwe et al [19] in Port-Harcourt reported a
male: female ratio of 1.4:1 of persons with T2DM.
The prevalence of MS in subjects with T2DM as de-
fined by the WHO criteria (see Table 1) was 87.1% (see
Table 2). The sex prevalence of the MS in T2DM males
was 88% while that of females was 86.5%. Ogbera [17]
reported a prevalence of MS of 86% with a sex preva-
lence of 86% in females and 83% in males similar to the
findings in this study and based on the new streamlined
criteria (NCEP-R). The study by Alebiosu and Odusan
[18] (which was based on the WHO criteria) reported a
prevalence of 25.2% of T2DM patients. This study was,
however, concluded in August, 2001. A previous study


















Urinary albumin excretion rate≥ 20 μg/min
or albumin/creatinine ratio
≥30 mg/g
Diagnosis Impaired FPG + any 2 criteria
WHR =waist-hip ratio, BMI = body mass index, FPG = Fasting plasma glucose.prevalence of 33.4% in persons with T2DM using the
WHO criteria. The work by Adediran [21] in 2003 re-
ported a prevalence of 51.5% in Lagos also using modi-
fied WHO criteria in persons with T2DM. In the control
group, the general prevalence of MS was 13.5% (13 out
of 96 persons). The sex prevalence of males with the MS
in the control group was 18.4% (7 out of 38 males) while
that of the females was 10.3% (6 out of 58 females). The
prevalence of MS in FDR study group was 16.67%. The
sex prevalence of MS in males of the FDR group was
13.1% (5 out of 38 males) while that of the female popu-
lation was of 18.4% (11 out of 58 females). The sex
prevalence of MS in the control group was higher in
males than females. A similar trend was observed in the
T2DM study group. However, in the FDR study group,
the sex prevalence was higher in females (see Table 3
and Figure 1).
From this study, the frequency of persons with the
metabolic syndrome increases with age. For persons with
T2DM, the frequency peaked at the age of 50–59 years
thereafter, it started declining. The FDR group also showed
a similar trend but peaked at the age of 60–69 years before
declining at the age range of 70 years and above. The con-
trol group also showed a similar trend of increasing fre-
quency with age, however, an early decline was observed.
The age range of 50–59 years and thereafter a steady in-
crease with age was observed through to the age of 70 years
and above. The chi square for linear trend was 97.1 with a
p-value = 0.01 (see Figure 2). This implies there is a linear
relationship between age and the metabolic syndrome.
Persons with the MS are generally known to have
increased risk for cardiovascular events; they are also
known to be overweight, hypertensive and to have
several metabolic abnormalities. The likely explanation
for this is the association of insulin resistance with
aging.
Social habits and lifestyle of the study groups
The prevalence of smoking in the control group was
11.5%, 1% in the FDR group and 12.9% in the T2DM
group which is higher when compared to other study
groups. Several studies [22,23] have identified smoking
as an independent risk factor for T2DM. The percentage
Figure 1 Distribution of persons with metabolic syndrome according









N = 96 N = 96 N = 124 X2 df p
Age group
30-39 years 7(7.3) 5(5.2) 7(5.6) 2.107 8 0.97
40-49 years 12(12.5) 13(13.5) 15(12.1)
50-59 years 32(33.3) 35(36.5) 45(36.3)
60-69 years 28(29.2) 31(32.3) 41(33.1)
70+ year 17(17.7) 12(12.5) 16(12.9)
Sex
Male 38(39.6) 38(39.6) 50(40.3) 0.017 2 0.99
Famale 58(60.4) 58(60.4) 74(59.7)
Level of education
No education 6(6.3) 17(17.7) 20(16.1) 15.282 6 0.01*
Primary 22(22.9) 24(25.0) 37(29.8)
Secondary 33(34.4) 16(16.7) 23(18.5)
Tertiary 35(36.5) 39(40.6) 44(35.5)
Marital status
Single 4(4.2) 4(4.2) 3(2.4) 8.582 6 0.19
Married 84(87.5) 86(89.6) 112(90.3)
Divorced 0(0) 0(0) 4(3.2)
Widowed 8(8.3) 6(6.3) 5(4.0)
F = Fishers exact test, df = degree of freedom, P = probability value, n = number,
N = sample size and * = p < 0.05 (statistically significant).
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was highest in patients with T2DM (40.3%) followed by
the control group (30.2%) and FDR (8.3%) and this was
statistically significant. This finding is in keeping with
the outcome of a study by Puepet and Ohwovoriole [24]
in Jos, Nigeria on the prevalence of risk factors for dia-
betes mellitus in a non-diabetic population which re-
ported that alcohol consumption appears to be one of
the dominant risk factors for development of type 2 DM
in this group of upland Nigerians. This was also similar
to findings in a study by Lombrail et al. [25] in Paris,
France to investigate the link between alcohol consump-
tion and glycoregulation/diabetes mellitus which re-
ported that alcohol consumption was independently
associated with diabetes mellitus.
About 60.4% of the control group and 45.8% of the
FDR group were not active (using the leisure activity
grading) compared to 45.2% of the T2DM group. This
finding was in keeping with the outcome of a study done
by Helmrich et al. [26] which examined patterns of
physical activity and other personal characteristics in re-
lation to the subsequent development of NIDDM in
5990 male alumni of the University of Pennsylvania.
They reported that increased physical activity is effective
in preventing NIDDM, and the protective benefit is es-
pecially pronounced in persons at the highest risk for
the disease. It was interesting to note that the T2DM
group had the lowest rate of physical inactivity. This
may be attributed to their possible adherence to lifestyle
modification advice (vis-a-vis exercise) given routinelyto sex.
Figure 2 Age distribution of persons with metabolic syndrome in the three study groups.
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betes association meetings and seminars. (See Table 4).
Comparison of biochemical variables between the control
and T2DM group
The mean FBS (117.2 ± 5.7 mg/dl) of the control group was
lower than that of the T2DM group (139.7 ± 17.1 mg/dl).
However, the mean total cholesterol and triglycerides were
higher in the control group than in the T2DM group. This
may be a reflection of the unrestricted diet in the control
group and a reflection of therapy in persons with T2DM. ATable 4 Shows a comparison of the social habits and








N = 96 N = 96 N = 124 X2 df p
Smoking
Yes 11(11.5) 1(1.0) 16(12.9) 10.579 2 0.01*
No 85(88.5) 95(99.0) 108(87.1)
Alcohol use
Yes 29(30.2) 8(8.3) 50(40.3) 28.247 2 0.01*
No 67(69.8) 88(91.7) 74(59.7)
Work related physical activity grade
Not active (sedentary) 43(44.8) 47(49.0) 52(41.9) 1.285 4 0.86
Moderately active 48(50) 43(44.8) 64(51.6)
Very active 5(5.2) 6(6.3) 8(6.5)
Leisure activity grade
Not active 58(60.4) 44(45.8) 56(45.2) 7.928 4 0.09
Moderate active 24(25.0) 37(38.5) 52(41.9)
Very active 14(14.6) 15(15.6) 16(12.9)
X2 = chi square, df = degree of freedom, p = probability value, n = number,
N = sample size and * = p < 0.05(statistically significant).few of the control subjects were on therapy for hyperten-
sion and the drug (thiazide) effect may reflect on their
mean blood glucose. The mean values of FBS, total choles-
terol, HDL cholesterol and LDL cholesterol were higher in
the persons with the MS in the T2DM group than in per-
sons with the MS in the FDR group. These findings were,
however, not significant. The mean values of triglyceride
were higher in persons with the MS in the FDR group than
in persons with the MS in the T2DM group (see Table 5).
Comparison of biochemical variables between the FDR
and control group
Comparing persons with the MS in the FDR group with
that of persons with the MS in the control group, the
persons with MS in the FDR group tended to be more
overweight, with more central obesity than persons with
the MS in the control group. The BMI was found to be
significantly different. This may imply an inherentTable 5 Biochemical variables of persons with the metabolic






n= 13 n = 108
Parameters Mean ± SD Mean± SD t df P
AGE(years) 55.6 ± 16.0 57.4 ± 10.4 0.54 119 0.59
FBS(mg/dl) 117.7 ± 5.6 139.7 ± 60.3 1.298 119 0.19
Total cholesterol(mg/dl) 190.9 ± 57.6 184.9 ± 47.9 0.358 119 0.68
HDL cholesterol (mg/dl) 60.7 ± 32.4 49.0 ± 15.8 2.180 119 0.03*
LDL cholesterol (mg/dl) 95.1 ± 48.1 107.2 ± 33.97 0.854 119 0.22
Triglycerides(mg/dl) 172.2 ± 48.1 117.2 ± 45.8 2.537 119 0.01*
FBS = Fasting blood sugar, HDL =High density lipoprotein, LDL = Low density
lipoprotein, MS =Metabolic syndrome and SBP = systolic blood pressure.
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sultant development of DM in some family members. Per-
sons in the FDR group had higher mean systolic and
diastolic blood pressures which may be a reflection of
their degree of being overweight or obese. The persons in
the control group with the MS had a slightly lower mean
FBS (117.2 ± 5.7 mg/dl) than persons in the FDR group
with the MS (118.4 ± 6.1 mg/dl). Although the difference
was not significant, this was not unexpected as previous
studies have demonstrated that the first degree relatives of
Type 2 diabetic patients constitute a high risk group for
DM [27]. Another study by Ma H et al. [28] on the preva-
lence of diabetes and prediabetes mellitus in the first-
degree relatives (FDR) of patients with type 2 diabetes
(T2DM) in Chengdu, China reported high risk of diabetes
in FDR of T2DM patients. The mean total cholesterol and
triglycerides were higher in persons with the MS in the
control group than that of persons with the MS in the
FDR group. This may be as a result of dietary adjust-
ments of the FDR persons because of their potential
risk for developing DM. These findings were, however,
not significant (See Table 6).
Comparison of biochemical features of persons with MS
in the T2DM and FDR group
The comparison of the clinical and biochemical features
of persons with the MS in the T2DM and the FDR
groups revealed that though persons with the MS in the
T2DM group had higher mean of WC, FBS, total choles-
terol, HDL, LDL and triglycerides compared to the FDR
subjects with the MS, this was not significant (See Table 7).
Profile of the metabolic abnormalities in the three study
groups
of the 38 males in the control group, 21.0% had impaired
fasting blood glucose, 36.8% had hypercholesterolaemia,Table 6 A comparison of biochemical indices of persons
with the metabolic syndrome in the control group and
the group of first degree relatives of persons living with






n = 13 n = 16
Mean ± SD Mean ± SD t df p
Age (years) 55.6 ± 16.0 54.4 ± 11.8 0.228 27 0.82
FBS (mg/dl) 117.7 ± 5.6 118.4 ± 6.1 0.335 27 0.74
Total cholesterol (mg/dl) 190.9 ± 57.6 171.1 ± 55.6 0.935 27 0.35
HDL cholesterol (mg/dl) 60.7 ± 32.4 48.6 ± 15.8 1.264 27
LDL cholesterol (mg/dl) 95.1 ± 48.1 99.3 ± 44.9 0.242 27 0.81
Triglycerides (mg/dl) 172.2 ± 48.1 155.6 ± 34.3 0.763 27 0.48
FBS = Fasting blood sugar, HDL = High density lipoprotein, LDL = Low density
lipoprotein, MS =Metabolic syndrome and SBP = systolic blood pressure.7.9% had low HDL cholesterol, 5.2% had elevated LDL
cholesterol and 10.5% had hypertriglyceridaemia. The
female in this group, however, had higher frequency
of biochemical abnormalities. Of the 58 females in
this group, 15.5% had impaired fasting blood glucose,
25.9% had hypercholesterolaemia, and 20.0% had low
HDL cholesterol level. Of the 38 males in the FDR group,
18.4% had impaired fasting blood glucose, 10.5% had
hypercholesterolaemia, 10.5% had low HDL cholesterol,
7.9% had elevated LDL cholesterol and 47.4% had hyper-
triglyceridaemia. Of the 58 female in this group, 24.1%
had impaired fasting blood glucose, 7.2% had hypercholes-
terolaemia, 6.9% had low HDL cholesterol level, 6.8%
had elevated LDL and 6.8% had hypertriglyceridaemia
(see Figure 3).
The mean values of TC, HDL and TG were lower in
the FDR of persons with T2DM. When compared to the
control group, persons in the FDR group had lower
means than those in the control group. This may be a
reflection of lifestyle adjustments they have made know-
ing their inherent risk of developing T2DM in future.
Such lifestyle adjustments may involve the avoidance of
refined sugars, reduced smoking and alcohol ingestion
and increased physical activities. Though persons in the
FDR group had a higher tendency of being overweight
than the persons in the control group, the smoking
habit, alcohol ingestion and use of herbal medications
(which may be alcohol based) were found to be signifi-
cantly higher in persons in the control group and these
may also explain the higher mean values of FBS, TC,
LDL and TG observed in them. Low HDL is the com-
monest metabolic abnormality in the FDR group, followed
by hypertriglyceridaemia, impaired fasting glucose, high
LDL, hypercholesterolaemia and microalbuminuria re-
spectively. The mean values of the major metabolic abnor-
malities in persons with T2DM were found to be relativelyTable 7 Comparison of biochemical variables of persons
with the metabolic syndrome in the type two diabetes
mellitus group and the group of first degree relatives of





n = 108 n = 16
Parameters Mean ± SD Mean ± SD t df P
Age (years) 57.4 ± 10.4 54.4 ± 11.8 1.037 122 0.30
FBS (mg/dl) 139.7 ± 60.3 118.4 ± 6.1 1.391 122 0.16
Total cholesterol (mg/dl) 184.9 ± 47.9 171.1 ± 55.6 1.058 122 0.29
HDL cholesterol (mg/dl) 49.0 ± 15.8 48.6 ± 15.8 0.099 122 0.92
LDL cholesterol (mg/dl) 107.2 ± 33.9 99.3 ± 44.9 1.463 122 0.14
Triglycerides (mg/dl) 117.2 ± 45.8 155.6 ± 34.3 1.782 122 0.07
FBS = Fasting blood sugar, HDL = High density lipoprotein, LDL = Low density
lipoprotein, MS =Metabolic syndrome and SBP = systolic blood pressure.
Figure 3 Profile of metabolic abnormalities in the three study groups.
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the T2DM group had higher mean biochemical indices
than that of the FDR group. Impaired fasting glycaemia is
the commonest metabolic abnormality in persons with
T2DM followed by microalbuminuria, low HDL, ele-
vated LDL, hypercholesterolaemia, and Hypertriglycer-
idaemia respectively. These findings suggest persons
with T2DM are a risk group we should routinely inves-
tigate periodically.
Conclusion
The prevalence of the metabolic syndrome in Nigerians
with T2DM is high compared to that of control and
non-diabetic first degree relatives. Abnormal glucose
reading is the commonest metabolic abnormality in per-
sons with T2DM followed by microalbuminuria, low
HDL, elevated LDL, hypercholesterolaemia, and Hyper-
triglyceridaemia respectively. Low HDL is the common-
est metabolic abnormality in the FDR group, followed by
hypertriglyceridaemia, impaired fasting glucose, high LDL,
and hypercholesterolaemia respectively while impaired
fasting glucose was noted in both the control and FDR.
Poor glycaemic control (FBS) and Hypertriglyceridaemia
are significant biochemical abnormalities in T2DM per-
sons with the MS. There is need for concerted efforts by
family members, communities, healthcare professionals
and patient based groups towards preventive based ap-
proach in the management of diabetes and metabolic syn-
drome; this can be achieved through increased emphasis
on lifestyle modification strategies such as exercise, in-
creased dietary restrictions and weight control strategiesespecially for those with impaired fasting glucose. A major
strength of this study is that it was the first study in Benin
City that looked at metabolic abnormalities in T2DM and
their FDR with metabolic syndrome: to the best of our
knowledge, there has not been any previous study on this
interesting group of subjects. Limitations that arose from
this study includes: 1) This was a small study therefore a
larger and specifically designed study is needed to evaluate
the metabolic abnormalities in T2DM patients, their FDR
and cohorts, 2) We did not measure HbA1c levels in this
study.
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